Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell therapy takes on Hard-to-Treat cancers

NCT ID NCT07410676

Disease control Sponsor: Essen Biotech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose interleukin-15 to support the cells, and some also get the drug pembrolizumab. The goal is to see if this combination is safe and can shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 83 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically confirmed advanced/metastatic solid tumor that is relapsed/refractory after standard therapy (or no standard therapy available). * Measurable disease per RECIST v1.1 (or iRECIST if applicable). * ECOG performance status 0-1 (or 0-2 as allowed). * Adequate organ function (thresholds modeled on NK protocols): * Platelets ≥ 75,000/µL; hemoglobin ≥ 9 g/dL; ANC ≥ 1,000/µL (unsupported by growth factors/transfusions as defined). * eGFR ≥ 60 mL/min/1.73m². * AST/ALT ≤ 3× ULN. * Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated). * LVEF ≥ 40% (by ECHO/MUGA/CMR). * If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids. Exclusion Criteria: * Pregnant or breastfeeding. * Any condition requiring systemic immunosuppression (e.g., \>5 mg prednisone/day or equivalent) during dosing window (topical/inhaled may be allowed). * Active autoimmune disease requiring systemic immunosuppression. * Uncontrolled bacterial, fungal, or viral infection. * Receipt of investigational agent within 28 days before first study drug. * Live vaccine within 6 weeks prior to lymphodepletion. * Known HIV positivity or active hepatitis B/C with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan). * Known allergy to investigational product components (example: albumin/human or DMSO). * Any medical/social condition likely to interfere with study compliance or increase risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm bronchogenic carcinoma cancer childhood leukemia colorectal cancer colorectal neoplasm disease esophageal cancer Esophageal Neoplasms gastric neoplasm glioblastoma kidney cancer leukemia liver cancer Liver Neoplasms lung cancer lung neoplasm malignant pancreatic neoplasm melanoma neoplasm Neoplasm Metastasis ovarian cancer pancreatic neoplasm prostate cancer sarcoma skin carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer Breast cancer (locally advanced or metastatic) Cancer Colorectal cancer Esophageal cancer Glioblastoma Kidney cancer Leukaemia Liver cancer (primary and metastatic) Lung cancer (diagnosis) Melanoma (skin cancer) Non-melanoma skin cancer Ovarian cancer Pancreatic cancer metastatic Sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • District One Hospital

    RECRUITING

    Beijing, Beijing Municipality, 086-373, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.